Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma

Inclusion Criteria: * Durie-Salmon Stage II or III multiple myeloma * Newly diagnosed either prior to receiving treatment or having completed induction therapy * Relapsed myeloma not previously transplanted within the past 5 years * Measurable serum and/or urine M-protein from prior to induction therapy documented and available. A positive serum free lite assay is acceptable * Age greater than 18 years old * ECOG performance status of 0 - 2 * Meet all institutional requirements for autologous stem cell transplantation * The patient must be able to comprehend and have signed the informed consent Exclusion Criteria: * Diagnosis of any of the following plasma cell disorders: POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein \[M-protein\] and skin changes) Non-secretory myeloma (no measurable protein on Serum Free Lite Assay) * Plasma cell leukemia * Amyloidosis * Use of corticosteroids (glucocorticoids) within 21 days of pre-transplant vaccine or bone marrow collection * Use of any myeloma-specific therapy other than lenalidomide within 21 days of pre-transplant vaccine * In a complete remission at the time of bone marrow collection * Infection requiring treatment with antibiotics, antifungal, or antiviral agents within seven days of vaccination or bone marrow collection * Participation in any clinical trial, within four weeks prior to vaccination or bone marrow collection on this trial, which involved an investigational drug or device * History of malignancy other than multiple myeloma within five years of vaccination or bone marrow collection, except adequately treated basal or squamous cell skin cancer * Active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosis) requiring systemic treatment. Hypothyroidism without evidence of Grave's Disease or Hashimoto's thyroiditis is permitted * Evidence of spinal cord compression at time of transplant